Plain-English translation of NCT04496349 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This research study is testing two experimental medications called and to see if they can help people with certain blood cancers — specifically T-cell prolymphocytic leukemia or non-Hodgkin's lymphoma — that have come back or stopped responding to previous treatments. Researchers believe these medications work by reawakening a natural cancer-fighting process in your body. The study will test whether the medication works best on its own or combined with another drug.
Many patients with these blood cancers run out of treatment options because their cancer stops responding to standard therapies. This trial exists to find a new treatment option for people in that situation, using a novel approach to fight cancer cells.
You likely qualify if…
You likely don't qualify if…
You would visit the research clinic regularly to receive the medication (either alone, or combined with , depending on which group you're in) and have your blood drawn to monitor how your body is handling the treatment and how your cancer is responding. The study is divided into different phases — some participants help doctors find the right dose, while others receive a set dose to test effectiveness and safety. You would need to avoid certain other medications during the trial, and your doctor will monitor you closely throughout.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
Ascentage Pharma Group Inc.
Enrollment target
~78 participants
Started
July 2021
Primary completion
May 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in November 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Genevieve Frank
Ascentage Pharma Group Inc.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.